Allergology International

This is a promotion site for the
Allergology International. You can see
the journal contents in Science Direct

Current Issue |
Volume 72, Issue 4
October 2023

Cover of Allergology International

Open Access ISSN: 1323-8930
2022 Impact Factor: 6.8
View More on Journal Insights
© 2023 Journal Citation Reports
© Clarivate Analytics, 2023

Appreciation to Reviewers

The Editors are deeply appreciative of their valuable expertise and contributions to AI. See more

Outstanding Reviewers 2022

About Allergology International

Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense.

The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following three categories: Original Articles, Review Articles, and Letters to the Editor.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

Editor's Choices

Original Article

Editor’s comment: Dupilumab, an anti-IL-4RA antibody, is approved for severe/refractory asthma inadequately controlled by existing therapies. Using an insurance claims data base, Fukunaga et al. investigated the real-world effects of dupilumab on asthma exacerbation risk and oral corticosteroid (OCS) use in Japanese individuals with asthma. They found that dupilumab reduced the annual incidence of severe asthma exacerbations by 43%. They also found that the mean OCS dosage decreased from 10.4 to 7.2 mg/day in chronic OCS users and that unscheduled outpatient visits and hospitalizations decreased.

Original Article

Editor’s comment: Chronic rhinosinusitis is classified into two major endotypes: neutrophilic and eosinophilic. Some patients with chronic rhinosinusitis are refractory to treatment. Iinuma et al. performed transcriptomic and proteomic analyses simultaneously for nasal polyp samples of non-eosinophilic chronic rhinosinusitis (nECRS) and eosinophilic chronic rhinosinusitis (ECRS). They found that the expression of multidrug resistance proteins 3 (MRP3) and MRP4 significantly increased in nECRS and ECRS, respectively. They also found that MRP3 and MRP4 expressions were positively correlated with the number of neutrophil and eosinophil infiltrates in polyps and were associated with the tendency to relapse in patients with ECRS, suggesting their involvement in treatment resistance.

Original Article

Editor’s comment: Allergen immunotherapy (AIT) effectively treats allergic diseases, including allergic rhinitis. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are available in Japan for AIT using standardized house dust mite (HDM) extract. Hamada et al. compared the effectiveness and safety of SCIT and SLIT with standardized HDM extract for pediatric patients with allergic rhinitis. They found that the HDM SCIT group showed significantly earlier efficacy than the HDM SLIT group. Regarding adverse effects, the incidence of systemic reactions was not significantly different between the two groups in the dose escalation phase but was higher in the HDM SCIT group than in the HDM SLIT group in the maintenance phase. The discontinuation rate was higher in the HDM SLIT group.

Review Series: Fungi and immune response: An update

In this issue, Yashiro, Iwata, and Imai provide reviews concerning ILC2s from the perspectives of basic researchers, allergologists, and dermatologists, respectively.

Invited Review Article

Denning et al. provide a thorough review of fungal asthma, including clinical characteristics, diagnosis, and treatment. They also discuss the importance of allergen avoidance, a foundational approach to allergy management, and reappraise the potential of antifungal drugs. In light of the emergence of drug-resistant fungi and the known side effects linked to current antifungal agents, the demand for novel antifungal solutions is mounting.

Invited Review Article

Agarwal et al. provide an encompassing review of Aspergillus and lower airway allergic diseases. Allergic fungal rhinosinusitis is a concomitant upper airway disease sharing pathophysiology with allergic bronchopulmonary aspergillosis.

Invited Review Article

Nakayama et al. offer an elegant review of allergic fungal rhinosinusitis as well as upper and lower airway allergic fungal diseases. Addressing the diverse nature of these diseases, the reviews provide a broad perspective on complex concepts, diagnostic criteria, and proposed terms, affording clarity to readers.

Invited Review Article

Ueno et al. supply a perceptive overview and delve into Cryptococcus infection mouse models, emphasizing the role of IL-33, an epithelial-derived cytokine. Of considerable value are the insights gleaned from animal models concerning how epithelial cytokines—potential targets for allergy treatment—contribute to fungal defense.

To Top